| Date | Partners | Compound / Disease area / Development phase | Type of agreement | Nature / Financial terms |
|---|---|---|---|---|
| 2010-03-03 | Abbott (USA) GSK (UK) |
molecular diagnostic test intended for use as an aid in selecting patients who have MAGE-A3 expressing melanoma tumors. / melanoma |
R&D development |
See details |
| 2010-03-03 | Allergan (USA) BMS (USA) |
AGN-209323 This orally administered small molecule was discovered as part of a collaboration between Allergan and the french biotech company ExonHit Therapeutics SA. / neuropathic pain |
manufacturing commercialization/ distribution development |
See details |
| 2010-03-02 | Zealand Pharma (Denmark) PolyTherics (UK) |
PEGylated peptides / metabolic, cardiovascular and gastrointestinal diseases | R&D |
See details |
| 2010-03-02 | Metabion (Germany) Polyplus-Transfection (France) |
ZNA™(Zip Nucleic Acids - oligocation-oligonucleotide conjugates that demonstrate an increased affinity for their complementary sequence without reduction in specificity) | licensing |
See details |
| 2010-03-02 | NAICONS scrl (New Anti-Infectives CONSortium -Italy) Sanofi-Aventis (France) |
pre-selected extracts derived for screening against relevant targets from gramnegative pathogens / infectious diseases | R&D |
See details |
| 2010-03-02 | TopoTarget (Denmark) SpePharm (the Netherlands) |
Savene® (desrazoxane - topoisomerase II inhibitor) / prevention of tissue lesions due to accidental extravasation of anthracycline (i.e. leakage of the drug from the blood vessel into which has been injected and where it is supposed to remain) | commercialization/ distribution other |
See details |
| 2010-02-25 | Evotec(Germany) Cubist Pharmaceuticals (USA) |
fragment-based drug discovery activities on antibacterial targets / undisclosed bacterial diseases |
R&D |
See details |
| 2010-02-25 | Regulus Therapeutics (USA) GSK (UK) |
microRNA therapeutics targeting microRNA-122 (miR-122 - liver-expressed microRNA that has been shown to be a critical endogenous “host factor” for the replication of HCV) / Hepatitis C Viral infection | R&D commercialization/ distribution development |
See details |
| 2010-02-24 | Zcube (Italy) QB3/Mission Bay Capital (USA) |
other |
See details | |
| 2010-02-24 | Basilea Pharmaceutica (Switzerland) Astellas Pharma (Japan) |
isavuconazole / invasive fungal infections caused by Aspergillus or other filamentous fungi and Candida fungi | licensing development marketing/ promotion |
See details |
| 2010-02-23 | CellCentric (UK) Takeda Pharmaceutical (Japan) |
epigenetic discovery programme / cancer | licensing commercialization/ distribution development |
See details |
| 2010-02-22 | GTC Biotherapeutics (USA) LFB (France) |
other |
See details | |
| 2010-02-21 | NasVax (Israel) Novartis Vaccines and Diagnostics (Switzerland) |
vaccines / influenza | R&D licensing |
See details |
| 2010-02-21 | Thallion Pharmaceuticals (Canada) LFB Biotechnologies (France) |
Shigamabs® / Shiga toxin-producing E. coli, or STEC, infections | commercialization/ distribution development |
See details |
| 2010-02-19 | Ark Therapeutics (UK) Merck &Co (USA) |
gene-based medicines | manufacturing |
See details |
